Boyer David W. sold $130K of NBIX

Neurocrine Biosciences, Inc. announced Eiry W. Roberts, M.D., will return as Chief Medical Officer, effective September 28, 2026. Dr. Sanjay Keswani's tenure as CMO ended on September 25, 2026. Dr. Roberts previously led key drug development programs at Neurocrine.

Neurocrine Biosciences (NBIX) reported positive Phase 4 study results for INGREZZA, showing significant patient improvement in tardive dyskinesia. The company also reported Q2 revenue growth of 39% to $959M, with INGREZZA sales up 15%. Neurocrine acquired Soleno Therapeutics, reducing cash reserves but expanding its drug portfolio. The stock trades at a forward P/E of 14.88.

Neurocrine Biosciences reported $1B in quarterly revenue, driven by Ingrezza, CRENESSITY, and VYKAT XR. Ingrezza saw double-digit growth, while CRENESSITY exceeded expectations. The company expects major pipeline catalysts in 2027–2028, according to a Wells Fargo conference transcript.

Nxera Pharma's partner, Neurocrine Biosciences, received FDA IND Acceptance for a Phase 2 study of NBI-1117567, an Alzheimer's cognition treatment. Nxera will receive a $10 million milestone payment, recognized as revenue in Q3 FY2026. Nxera retains development rights in Japan.

Neurocrine Biosciences (NBIX) shares fell about 3.1% to $156.94 after three Prader-Willi patient groups issued a joint statement citing post-marketing safety data for Neurocrine’s Vykat XR, including seven patient deaths and 100+ serious adverse events reported to the FDA. The groups did not claim causality. CEO Kyle Gano disputed a link. Investors also weighed INGREZZA drug-pricing concerns; Q2 2026 revenue was reported above $950M.

Simply Wall St says Neurocrine Biosciences (NBIX) reported Q2 2026 revenue of $959 million and net income of $144.4 million. It also filed a $742 million shelf registration for 4,000,000 common shares tied to an ESOP offering. The piece links stronger profitability and potential dilution to investor expectations around INGREZZA and CRENESSITY.